
Opinion|Videos|December 5, 2024
The JAK Revolution in Vitiligo
Author(s)James Song, MD, FAAD
Key Takeaways
James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5























